Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia
Open Access
- 6 October 2011
- journal article
- Published by American Society of Hematology in Blood
- Vol. 118 (14), 3818-3823
- https://doi.org/10.1182/blood-2011-04-351502
Abstract
We conducted this study to determine the feasibility and safety of cladribine followed by rituximab in patients with hairy cell leukemia including the vari-ant form (HCLv). Cladribine 5.6 mg/m2 given IV over 2 hours daily for 5 days was followed ∼ 1 month later with rituximab 375 mg/m2 IV weekly for 8 weeks. Responses were recorded and BM minimal residual disease (MRD) was evaluated after the completion of rituximab. Thirty-six patients have been treated including 5 with HCLv. Median age was 57 years (range, 37-89). All patients (100%) have achieved complete response (CR), defined as presence of no hairy cells in BM and blood with normalization of counts (absolute neutrophil count [ANC]> 1.5 × 109/L, hemoglobin [Hgb] > 12.0 g/dL, platelets [PLT] > 100 × 109/L), as well as resolution of splenomegaly. There were no grade 3 or 4 nonhematologic adverse events directly related to the treatment. Only 1 patient (with HCLv) has relapsed; median CR duration has not been reached (range,1+-63+ months). Three patients with HCLv died including 1 with relapsed disease and 2 from unrelated malignancies. Median survival duration has not been reached (range, 2+-64+ months). Treatment with clad-ribine followed by rituximab is effective tk;4and may increase CR rate. This study was registered at www.clinicaltrials.gov as NCT00412594.This publication has 32 references indexed in Scilit:
- BRAFMutations in Hairy-Cell LeukemiaThe New England Journal of Medicine, 2011
- Evidence of canonical somatic hypermutation in hairy cell leukemiaBlood, 2011
- Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup StudyJournal of Clinical Oncology, 2010
- How I treat hairy cell leukemiaBlood, 2010
- VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapyBlood, 2009
- Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behaviorBlood, 2009
- Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 StudyJournal of Clinical Oncology, 2009
- Soluble CD22 as a tumor marker for hairy cell leukemiaBlood, 2008
- PCR Analysis of Immunoglobulin Heavy Chain (IgH) and TcR-γ Chain Gene Rearrangements in the Diagnosis of Lymphoproliferative Disorders: Results of a Study of 525 CasesLaboratory Investigation, 2000
- Lasting Remissions in Hairy-Cell Leukemia Induced by a Single Infusion of 2-ChlorodeoxyadenosineThe New England Journal of Medicine, 1990